Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

Inclusion Criteria:

* Histologically confirmed glioblastoma

  * Newly diagnosed disease
* Scheduled to receive standard post-surgical (i.e., biopsy or resection) temozolomide and radiotherapy
* Must have residual, contrast-enhancing tumor (≥ 1 centimeter in ≥ 1 dimension)
* Patients must be maintained on a stable corticosteroid regimen for 5 days prior to their baseline scan and for 5 days prior to their first vascular MRI; the dose of steroids should remain the same during the baseline vascular MRIs
* Archival tumor tissue available for molecular analysis
* No intratumoral hemorrhage or peritumoral hemorrhage by MRI
* Karnofsky performance status 60-100%
* Leukocytes ≥ 3,000/mcl
* Absolute neutrophil count ≥ 1,500/mcL
* Platelet count ≥ 100,000/mcL
* Hemoglobin ≥ 8 g/dL
* Total bilirubin normal
* AST/ALT ≤ 2.5 times upper limit of normal
* Creatinine normal OR creatinine clearance ≥ 60 mL/min
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* Proteinuria ≤ 1+ on two consecutive dipsticks ≥ 7 days apart
* Mini-mental status examination score ≥ 15
* Must be able to tolerate MRI and must consent to participate in additional Vascular Imaging Procedures per protocol

  * CT scans cannot be substituted for MRI
* Mean QTc ≤ 500 msec (with Bazett's correction) by electrocardiogram
* No concurrent malignancy except curatively treated basal cell or squamous cell carcinoma skin cancer or carcinoma in situ of the cervix or breast

  * Patients with prior malignancies must be disease-free for ≥ 5 years
* No history of familial long QT syndrome or other significant ECG abnormality
* No history of allergic reactions attributed to compounds of similar chemical or biologic composition to cediranib
* No uncontrolled intercurrent illness including, but not limited to, any of the following:

  * Hypertension (e.g., blood pressure \> 140/90 mm Hg)
  * Ongoing or active infection
  * Symptomatic congestive heart failure
  * Unstable angina pectoris
  * Cardiac arrhythmia
  * Psychiatric illness/social situations that would preclude study compliance
* No known coagulopathy that increases risk of bleeding
* No history of clinically significant hemorrhages in the past
* No New York Heart Association class III-IV heart disease
* No condition requiring concurrent drugs or biologics with proarrhythmic potential
* No other concurrent chemotherapy agents, investigational agents, or biologic therapy
* No prior chemotherapy, radiotherapy, or any experimental therapy for this disease
* No prior IV bevacizumab for any other medical condition
* No prior carmustine implant (Gliadel Wafer)
* No prior brachytherapy or radiosurgery for this disease
* More than 30 days since prior and no other concurrent investigational agents or participation in an investigational therapeutic trial
* At least 2 weeks since prior and no concurrent enzyme-inducing anti-epileptic drugs (EIAEDs)

  * Concurrent non-EIAEDs allowed
* No concurrent CYP450-inducing anticonvulsants
* No concurrent anticoagulants (e.g., dalteparin, warfarin, or low-molecular weight heparin)

  * If patients require warfarin or other anticoagulants (e.g., low-molecular weight heparin) while on study, then patient may continue treatment
* No concurrent combination antiretroviral therapy for HIV-positive patients
* No concurrent VEGF inhibitors
* No concurrent pentamidine
* No concurrent herbal or nontraditional medications